期刊简介
本杂志是由中华人民共和国卫生部主管，同济医科大学附属协和医院主办，国内外公开发行的学术性期刊，被国家科技部列为“中国科技论文统计源期刊”，被中国科学文献计量评价研究中心认定为《中国科学引文数据库》来源期刊。设有专家笔谈、临床研究、实验研究、研究报告、综述、进修苑、学术争鸣、经验介绍及病例报告等栏目。
往期目录
-
1999
-
2000
-
2001
-
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
首页>临床血液学杂志
- 杂志名称：临床血液学杂志
- 主管单位：中华人民共和国教育部
- 主办单位：华中科技大学同济医学院附属协和医院 北京大学医学院血研所
- 国际刊号：1004-2806
- 国内刊号：42-1284/R
- 出版周期：双月刊
期刊荣誉：中国核心期刊数据库收录期刊期刊收录：国家图书馆馆藏, 万方收录(中), 上海图书馆馆藏, CA 化学文摘(美), 统计源核心期刊(中国科技论文核心期刊), 知网收录(中), 维普收录(中)
重型再生障碍性贫血的非移植治疗:第58届美国血液学会年会报道
刘为易；胡晓梅
关键词：骨髓衰竭, 再生障碍性贫血, 血小板生成素受体, 雄激素, 端粒
摘要：Non-transplant therapeutic options for acquired and constitutional aplastic anemia have significantly expanded during the last 5 years.In the future,transplant may be required less frequently.That trilineage hematologic responses could be achieved with the single agent eltrombopag in refractory aplastic anemia promotes new interest in growth factors after years of failed trials using other growth factor agents.Preliminary results adding eltrombopag to immunosuppressive therapy are promising,but long-term follow-up data evaluating clonal evolution rates are required before promoting its standard use in treatment-naive disease.Danazol,which is traditionally less preferred for treating cytopenias,is capable of preventing telomere attrition associated with hematologic responses in constitutional bone marrow failure resulted from telomere disease.Non-transplant therapy for bone marrow failure will be summarized in this paper based on the reports in the 58th ASH annual meeting.
友情链接